T1	Participants 37 127	planned coronary stent implantation in patients with chronic kidney disease (ESPRIT Trial)
T2	Participants 194 229	patients with mild renal impairment
T3	Participants 386 449	patients who underwent percutaneous coronary intervention (PCI)
T4	Participants 454 612	analyzed 48-hour and 30-day outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial
T5	Participants 614 771	Patients were randomly assigned to placebo or eptifibatide as an adjunct to stent implantation (1,755 with CrCl > or =60 ml/min and 289 with CrCl <60 ml/min)
